Trials / Completed
CompletedNCT00297765
Optimizing Prograf® Therapy in Renal Transplant Patients
OPTIMA (Optimizing Prograf® Therapy in Renal Transplant Patients)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 323 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study to determine the optimal dose and blood level of Prograf® in long-term maintenance of kidney transplant patients.
Detailed description
A 3 arm study (2 Active, 1 Active Control) to determine the optimal dose and blood level of Prograf® in long-term maintenance of kidney transplant patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tacrolimus, Prograf® |
Timeline
- Start date
- 2003-01-01
- Completion
- 2006-03-01
- First posted
- 2006-03-01
- Last updated
- 2008-08-26
Locations
42 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00297765. Inclusion in this directory is not an endorsement.